Dossier Submission Support for Medical Device & IVD Manufacturers
Compile, audit, or submit your technical documentation with a team that has reviewed files as a manufacturer, as an auditor, and from inside Notified Body review.
What causes dossier submission delays and rejections?
What causes dossier submission delays and rejections?
Dossier submission support is Qserve's service for compiling, reviewing, and submitting the technical documentation a device needs for MDR, IVDR, FDA, or country-specific market access. Most delays trace back to one of four recurring gaps, and each is avoidable if it's caught early rather than at review.
- Incomplete or outdated technical documentation
- A design history file that was never restructured into a submission-ready dossier
- A regulatory pathway decided too late in development
- Internal reviewers seeing the file for the first time days before the deadline
None of these require starting over. They require a structured look at the file before a regulator or Notified Body takes one.
What's included in dossier submission support
Qserve compiles, reviews, and submits technical documentation across five connected workstreams: EU MDR and IVDR technical files, US FDA submissions, country-specific registration dossiers, pre-submission gap assessments, and direct interface with your Notified Body or regulatory agency during review.
EU MDR & IVDR technical file compilation
We structure, write, and compile technical files to EU MDR Annex II & III technical documentation and IVDR 2017/746 Annex II & III, covering device description, labelling, design and manufacturing information, demonstration of general safety and performance requirements, benefit-risk analysis, verification and validation data, and clinical or performance evaluation.
A complete file typically includes:
- Device description and specifications
- Complete labelling and instructions for use
- Design and manufacturing information
- Demonstration of general safety and performance requirements
- Benefit-risk analysis and risk management documentation
- Verification and validation testing results
- Pre-clinical data
- Clinical evaluation and post-market clinical follow-up plans and reports
- Post-market surveillance plans and periodic safety update reports
- Additional evidence for devices incorporating a medicinal substance, animal or human tissue, CMR or endocrine-disrupting substances, sterile devices, measuring devices, or connected devices
US FDA submissions — 510(k), De Novo, and PMA
We prepare and manage FDA 510(k) premarket notification, FDA De Novo classification request, and FDA premarket approval (PMA) submissions, plus FDA pre-submission meetings. Each pathway asks a different question. Substantial equivalence for a 510(k), first-of-kind safety and effectiveness for a De Novo, full scientific review for a PMA. We build the file to match the pathway rather than a generic template.
Country-specific registration dossiers
Once a global technical file exists, we adapt it into country-specific dossiers for Global Registrations, translating, reformatting, and adding region-specific annexes so one core file supports many registrations instead of starting from zero for each market.
Gap assessments before you submit
A dossier gap assessment reviews existing documentation against the specific Annex or FDA pathway it needs to satisfy and flags what's missing before a reviewer does. It's narrower than a full Audits & Assessments the focus is submission-readiness of the file itself, not the quality system as a whole.
Notified Body and agency interface
During review, we manage the questions, deficiency letters, and negotiations that come back from a Notified Body or regulatory agency, drafting responses that resolve the underlying gap rather than the narrowest reading of the question, so one round of queries doesn't turn into three.
When should you bring in dossier submission support?
Bring in dossier submission support when compiling a first technical file, transitioning a legacy device to MDR or IVDR, responding to a deficiency letter under time pressure, or coordinating a multi-country registration where one technical file has to become several regional dossiers.
- A first-ever submission, with no internal template to work from
- A legacy device moving from the old Directives onto MDR or IVDR
- An internal RA or QA team stretched thin or between hires. See Interim Support
- A deficiency letter or Notified Body question that needs a structured, fast response
- A simultaneous rollout across multiple countries
Satisfied Clients
Our Dossier Submission Support services cover multiple disciplines. Discover them all:
Submission file / documentation MDR
We structure, compile, and write complete submission files aligned with current regulatory MDR standards, ensuring consistency and traceability across all required components. Our team manages the end-to-end documentation process, from gap assessments to final dossier delivery.
US FDA submission support for 510(k), PMA, pre-submission, and DeNovo
We provide strategic and hands-on support for all FDA pathways, including pre-submission meetings, 510(k), De Novo, and PMA filings. Our experts ensure your submissions are scientifically robust, well-structured, and aligned with FDA expectations.
Submission file / documentation for country registration
We prepare localized dossiers based on global technical files, adapting documentation to meet the specific regulatory requirements of each target country. Our team manages translations, formatting, and region-specific annexes to streamline international registrations.
How Qserve reduces submission risk
Our consultants have reviewed technical files as manufacturers, as auditors, and from inside Notified Body review teams, so we know which parts of a file draw real scrutiny and which are checkbox items. Every project starts with a gap assessment rather than a blank template, so drafting time goes where the risk actually sits.
If the regulatory pathway itself isn't decided yet, that's an earlier step handled by Regulatory Strategy Support. Dossier submission support picks up once the pathway is set and the file needs building, reviewing, or defending.
Whether the file is half-built, fully drafted, or still a blank page, we can pick it up from where it stands.
How Qserve reduces submission risk
Our consultants have reviewed technical files as manufacturers, as auditors, and from inside Notified Body review teams, so we know which parts of a file draw real scrutiny and which are checkbox items. Every project starts with a gap assessment rather than a blank template, so drafting time goes where the risk actually sits.
If the regulatory pathway itself isn't decided yet, that's an earlier step handled by Regulatory Strategy Support. Dossier submission support picks up once the pathway is set and the file needs building, reviewing, or defending.
Whether the file is half-built, fully drafted, or still a blank page, we can pick it up from where it stands.
Couldn't find your question?
Do you review dossiers we've already drafted, or build them from scratch?
Both. We review and strengthen a dossier that's already drafted, pick up a partially complete file, or build the technical documentation from a blank page. The starting point changes the scope of work, not whether we can help.
How early should regulatory input start in product development?
Ideally at the concept or design phase. Early input sets the correct regulatory pathway, avoids rework once testing is underway, and keeps technical documentation and clinical data collection aligned with what the target market actually requires.
How long does a dossier submission project typically take?
It depends on device class and how much documentation already exists. A gap assessment on an existing file can run a few weeks; building a full MDR technical file or FDA submission from scratch typically takes several months, driven mostly by how much clinical or performance evidence still needs generating.
Do you work within our existing QMS and templates, or use your own?
We work within existing QMS documentation and templates wherever they meet the applicable Annex or FDA structure, and only recommend a change where the current template would create gaps at review. The goal is a submission-ready file, not a rebuild of the quality system.
Latest blogs
.png)
Class B and Class A-sterile IVDs now need notified body sign-off. Get the 8-step plan to apply before May 26, 2027, and what the IVDR 2.0 proposal could change.
-4.png)
ISO 9001:2026 has been published: translate ISO 9001:2026 developments in your supply chain into effective ISO 13485 supplier controls.
Understand how EUDAMED and Swissdamed differ, where their data aligns and how to prepare for both 2026 registration deadlines.